Can you provide a breakdown of dupixent's 2019 and 2020 sales?

I can help, but I need one quick clarification first: when you say “DuPixent,” do you mean dupilumab (product-level sales) or Regeneron/Biogen company segment revenue that includes dupilumab?

Also, “sales” can be reported as:
- Worldwide net product sales (manufacturer reporting), or
- U.S. net sales, or
- quarterly vs full-year.

If you confirm which geography (worldwide vs U.S.) and which type of sales metric, I’ll format a clean 2019 and 2020 breakdown (typically by indication where that disclosure is available, otherwise by consolidated product sales).

In the meantime, here are the commonly cited full-year worldwide dupilumab net sales (manufacturer/product-level) figures:
- 2019: ~$3.0–$3.2 billion
- 2020: ~$5.2–$5.3 billion

However, I don’t want to risk giving you the wrong “breakdown” without knowing what level of detail you need (by indication, by region, or by quarter).

Reply with:
1) Worldwide or U.S.?
2) Product net sales vs company reported revenue?
3) Do you want by indication (e.g., asthma, AD, CRSwNP, atopic dermatitis, etc.) or just total sales by year?